Skip to main content
Smart Investors Daily
TC

OTC · TCGGY

Tecan Group AG

Healthcare · Medical - Instruments & Supplies

$36.00

Up+$0.00 (+0.00%)

Updated Sep 14, 2026, 1:03 AM

SID Score

4.9/10

Composite research score

Smart Money

Institutional and insider signal

Market cap
2.29B
P/E ratio
25.67
Dividend yield
2.04%
52-week range
— – —
Volume
17
Avg. volume
3.36

Price performance

TCGGY price history

1M range · 0 trading sessions · Daily adjusted prices

TCGGY does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest TCGGY news

The latest Smart Investors Daily articles mentioning TCGGY.

TCGGY research

Overview

Company profile and research snapshot.

Company profile

TECAN GROUP AG U/ADR

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Average target
Implied upside
Analysts
TCGGY recent ratings
DateFirmRatingTarget
Jul 13, 2026BERENBERGBuy
Jun 22, 2026ODDO BHFBuy
Jan 26, 2026BERENBERGBuy
Jan 25, 2026BERENBERGBuy
Jan 9, 2026ODDO BHFBuy
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 4, 2026

Tecan schedules conference call on August 11th to discuss half year 2026 financial results

Männedorf, Switzerland, August 4, 2026 – The Tecan Group AG (SIX Swiss Exchange: TECN) will hold a conference call to discuss the financial results for the first half year 2026 on Tuesday, August 11th, 2026, at 09:00 CEST. The results will be published on August 11th, 2026, at 7:00 CEST. The conference call will be audio-webcast with synchronized presentation slides. The webcast and a replay of the webcast will be made available in the "Investor Relations" section of Tecan's website www.tecan.co

Yahoo · Jun 24, 2026

Tecan Accelerates Data-Driven Lab Journey With Agentic AI Developments Powered by NVIDIA

MÄNNEDORF, Switzerland, June 24, 2026--Tecan (SIX Swiss Exchange: TECN), a global provider of laboratory automation and solutions, today announced the integration of Agentic AI capabilities into its lab analytics platform Introspect, leveraging NVIDIA BioNeMo Agent Toolkit. The NVIDIA BioNeMo Agent Toolkit enables AI agents to access scientific AI capabilities directly within the Introspect platform, helping laboratories to optimize operations. Agentic AI will allow laboratories to move beyond t

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.